Boehringer snaps up cancer vaccine developer
German pharma major Boehringer Ingelheim has taken over Swiss cancer immunotherapy player AMAL Therapeutics.
ADVERTISEMENT
About Uta Mommert
This author has not written his bio yet.
But we are proud to say that Uta Mommert contributed 241 entries already.
Entries by Uta Mommert
€28.5m for microalgae expert Microphyt
French microalgae specialist Microphyt has raised €28.5m to develop its microalgae portfolio for nutrition and cosmetics.
€8m for universal flu vaccine
French biotech Osivax has raised €8m to fast-track development of its lead flu vaccine candidate – and branch out to Belgium.
BioNTech pulls in massive €290m financing
It is one of the largest single private funding rounds a biotech company in Europe has ever pulled off. German biotech BioNTech managed to raise US$325m (€290m) in an upsized Series B round to boost its immuno-oncology pipeline.
Biophytis launches €9m Nasdaq IPO
Biophytis has priced its IPO on Nasdaq Paris. The company aims to raise up to €10.8m to advance its lead drug candidate under development for the treatment of neuromuscular diseases.
€30m for Evotec cancer spin-out
German biotech group Evotec has once more launched a spin-off: Breakpoint Therapeutics GmbH is focusing on treating cancer patients by targeting DNA damage responses.
Partnership in pursuit of new antibiotics class
A new collaboration aims to the urgent fight against antimicrobial resistant bacteria. Lyon-headquartered biotech Nosopharm has teamed up with German drug discovery company Evotec SE to develop a novel antibiotics class.
Drug puts CAR T activity on hold
German researchers have found a way to curb the activity of CAR T cells, even while keeping their cancer-fighting properties intact.
License deal in oncolytic virotherapies
Oncovita has been granted the exclusive license to an immuno-oncolytic measles virus platform developed by the Institut Pasteur. Based on the technology, the Paris-based biotech plans to develop cancer therapies.
Double win for Novartis
It was a good day for Novartis: A second drug with huge selling potential has been approved for the US market. The FDA gave the go ahead for breast cancer drug Piqray (alpelisib), the first and only treatment developed specifically for patients with a PIK3CA mutation in HR+/HER2-advanced breast cancer.